 Aileron Therapeutics ALRN announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer SCLC against chemotherapy-induced toxicity, a concept known as chemoprotection or myelopreservation. The Company expects to enroll approximately 8 patients into this dose optimization expansion cohort to further evaluate the selected dose for chemoprotection from topotecan-induced bone marrow toxicities. 